Fortress Biotech, Inc (FBIOP)

Etorro trading 970x250
Fortress Biotech, Inc (FBIOP) Logo

About Fortress Biotech, Inc

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York. Address: 2 Gansevoort Street, New York, NY, United States, 10014

Fortress Biotech, Inc News and around…

Latest news about Fortress Biotech, Inc (FBIOP) common stock and company :

Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.
13 Jan, 2022 Yahoo! Finance

Franchise includes AMZEEQ® for the treatment of acne and ZILXI® for the treatment of rosacea, and a development-stage dermatology program (FCD105) along with the MST proprietary platform Acquisition expands Journey Medical’s portfolio to nine marketed dermatology products East West Bank Credit agreement expanded to $30.0 million SCOTTSDALE, Ariz., Jan. 13, 2022 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focus

Fortress Biotech, Inc.'s (NASDAQ:FBIO) Path To Profitability
11 Jan, 2022 Yahoo! Finance

With the business potentially at an important milestone, we thought we'd take a closer look at Fortress Biotech, Inc.'s...

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR
07 Jan, 2022 Yahoo! Finance

WORCESTER, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that interim Phase 1/2 data on MB-106, a CD20-targeted, autologous CAR T cell therapy for patients with relapsed or refractory B-cell non-Hodgkin lymphomas (“NHL”) and chronic l

Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference
06 Jan, 2022 Yahoo! Finance

MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the H.C. Wainwright BioConnect Virtual Conference scheduled to take place from Monday, January 10 throu

Mustang Bio to Participate in Three January 2022 Virtual Investor Conferences
05 Jan, 2022 Yahoo! Finance

WORCESTER, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that Manuel Litchman, M.D., President and Chief Executive Officer, will participate in three virtual investor conferences in January 2022. Details of the events are as follows:

Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21
21 Dec, 2021 Yahoo! Finance

NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, announced that Lindsay A. Rosenwald, M.D., Chairman and Chief Executive Officer, will ring the closing bell at the Nasdaq MarketSite in Times Square today, Tuesday, December 21, 2021 at 4:00 p.m. EST. Fortress is celebr

Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
16 Dec, 2021 Yahoo! Finance

Helocyte, Inc., a partner company of Fortress Biotech, is developing Triplex for the treatment of cytomegalovirus Clinical trial will evaluate whether Triplex, which was developed by City of Hope, is safe and effective in eliciting a CMV-specific immune response in people living with HIV and is thus able to reduce CMV replication NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing

Mustang Bio Added to the NASDAQ Biotechnology Index
16 Dec, 2021 Yahoo! Finance

WORCESTER, Mass., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that the company has been added to the NASDAQ Biotechnology Index® (NASDAQ: NBI). The annual re-ranking of the NASDAQ Biotechnology Index will become effective prior to market o

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
13 Dec, 2021 Yahoo! Finance

95% overall response rate, 65% complete response rate and favorable safety profile in patients treated with modified cell manufacturing process Data presented at the 63rd American Society of Hematology (ASH) Annual Meeting Key opinion leader conference call on Thursday, December 16, 2021, at 2:30 p.m. EST WORCESTER, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs

Journey Medical Corporation Reports Third Quarter 2021 Financial Results and Recent Corporate Highlights
10 Dec, 2021 Yahoo! Finance

Generated record net revenues of $19.6 million for the third quarter of 2021 Completed initial public offering of common stock and raised $31.2 million in net proceeds SCOTTSDALE, Ariz., Dec. 10, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced financial results and recent

Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
09 Dec, 2021 Yahoo! Finance

Webinar to be held on Thursday, December 16, 2021, at 2:30 p.m. ET WORCESTER, Mass., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Mustang Bio, Inc. (“Mustang”) (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, today announced that it will host a key opinion leader (“KOL”) webinar on MB-106, the Company’s CD20-targeted, autologous CAR

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer
08 Dec, 2021 Yahoo! Finance

WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC). The primary endpoint for the CONTERNO Phase 3 trial is overall survival

Journey Medical Corporation to Present at the Benzinga Global Small Cap Conference
07 Dec, 2021 Yahoo! Finance

SCOTTSDALE, Ariz., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, today announced that management will present at the Benzinga Global Small Cap Conference, which is being held virtually from December 8 – 9, 2021. Claude Maraoui, President and Chief Executive Officer, and Ernie

Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a New Drug Application for CUTX-101, Copper Histidinate, for Treatment of Menkes Disease
07 Dec, 2021 Yahoo! Finance

NEW YORK and SOLANA BEACH, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from its licensing partner Sentynl Therapeutics, Inc. (“Sentynl”), a wholly owned subsidiary of Cadila Healthcare Limited (“Zydus”), today announced the initiation of a rolling submission of a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for CUTX-101 (“Copper Histidinate”) f

Journey Medical Corporation Introduces Expanded Board of Directors
29 Nov, 2021 Yahoo! Finance

SCOTTSDALE, Ariz., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (NADSAQ: DERM), a partner company of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), expanded the company’s board of directors as part of its recent initial public offering to include four new independent directors: Jeffrey Paley, M.D., Justin Smith, Miranda Toledano and Neil Herskowitz. Lindsay Rosenwald, M.D., Executive Chairman, and Claude Maraoui, President and Chief Executive Officer, re

Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option
17 Nov, 2021 Yahoo! Finance

NEW YORK, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (the “Company”) (NASDAQ: ATXI), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that the underwriter of its previously announced underwritten public offering has exercised, in full, its option to purchase an additional 292,018 shares of common stock at a price of $1.34 per share. Total gross proceeds to the Company from the offering, including the funds received from the

Journey Medical Corporation Announces Closing of Initial Public Offering
16 Nov, 2021 Yahoo! Finance

SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions, and a subsidiary of Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), today announced the closing of its initial public offering of common stock of 3,520,000 shares at a public offering price of $10.00 per shar

Fortress Biotech (FBIO) Reports Q3 Loss, Tops Revenue Estimates
15 Nov, 2021 Yahoo! Finance

Fortress Biotech (FBIO) delivered earnings and revenue surprises of -225.00% and 14.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights
15 Nov, 2021 Yahoo! Finance

Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record Journey Medical Corporation, a Fortress partner company, launched its $35.2 million initial public offering AstraZeneca acquired Caelum Biosciences; Fortress received $56.9 million upfront1 Rolling NDA submission for CUTX-101 for the treatment of Menkes disease is expected to be initiated in the fourth quarter of 2021 Top-line results from registration-enabling study of cosibelimab in metasta

Journey Medical Stock Drops After IPO Market Delivers Record Week. What to Know.
13 Nov, 2021 Yahoo! Finance

After a record-breaking week in the initial public offering market, only one company made its public debut Friday. Roughly 14 companies went public this week via traditional IPOs, raising $14.9 billion, according to Refinitiv. Shares of Rivian rose more than 29% Wednesday, when the company made its public debut and saw its valuation surpass some of the biggest traditional auto makers.

Fortress Biotech's Series A Preferred Stock Shares Cross 9% Yield Mark
03 Nov, 2021 FinancialContent

In trading on Wednesday, shares of Fortress Biotech Inc's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) were yielding above the 9% mark based on its monthly dividend (annualized to $2.3438), with shares changing hands as low as $25.96 on the day. This compares to an average yield of 8.50% in the "Drugs & Pharmaceuticals" preferred stock category, according to Preferred Stock Channel..

Fortress Biotech's Series A Preferred Stock Crosses Above 9% Yield Territory
12 Jul, 2021 FinancialContent

In trading on Monday, shares of Fortress Biotech Inc's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) were yielding above the 9% mark based on its monthly dividend (annualized to $2.3438), with shares changing hands as low as $26.00 on the day. This compares to an average yield of 8.52% in the "Drugs & Pharmaceuticals" preferred stock category, according to Preferred Stock Channel..

Fortress Biotech Inc's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock Shares Cross 10% Yield Mark
29 Mar, 2021 FinancialContent

In trading on Monday, shares of Fortress Biotech Inc's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) were yielding above the 10% mark based on its monthly dividend (annualized to $2.3438), with shares changing hands as low as $22.63 on the day. This compares to an average yield of 9.61% in the "Drugs & Pharmaceuticals" preferred stock category, according to Preferred Stock Channel..

Fortress Biotech's Series A Preferred Stock Shares Cross 12% Yield Mark
23 Dec, 2020 FinancialContent

In trading on Wednesday, shares of Fortress Biotech Inc's 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock (FBIOP) were yielding above the 12% mark based on its monthly dividend (annualized to $2.3438), with shares changing hands as low as $19.35 on the day. This compares to an average yield of 10.33% in the "Drugs & Pharmaceuticals" preferred stock category, according to Preferred Stock Channel..

Fortress Biotech, Inc (FBIOP) is a NASDAQ Common Stock listed in , ,

970x250